Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 18/20 | 1.00 |
| ▸ | MCHR1 | Q99705 | 3/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 15/20 | 0.68 |
| ▸ | ADRA1B | P35368 | 15/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3986844 | 0.95 | ADRA1A (0.90) | ADRA1AMCHR1DRD2ADRA1DADRA1B | |
| SCHEMBL31060823 | 0.93 | ADRA1A (0.88) | ADRA1AMCHR1DRD2ADRA1DADRA1B | |
| SCHEMBL6764196 | 0.90 | ADRA1A (0.81) | ADRA1AMCHR1DRD2ADRA1DADRA1B | |
| SCHEMBL6712292 | 0.88 | ADRA1A (0.79) | ADRA1AMCHR1DRD2ADRA1DADRA1B | |
| SCHEMBL7091765 | 0.88 | ADRA1A (0.79) | ADRA1AMCHR1DRD2ADRA1DADRA1B | |
| SCHEMBL7093785 | 0.88 | ADRA1A (0.79) | ADRA1AMCHR1DRD2ADRA1DADRA1B | |
| SCHEMBL6710975 | 0.88 | ADRA1A (0.79) | ADRA1AMCHR1DRD2ADRA1DADRA1B | |
| SCHEMBL6713510 | 0.88 | ADRA1A (0.78) | ADRA1AMCHR1DRD2ADRA1DADRA1B | |
| SCHEMBL7096153 | 0.88 | ADRA1A (0.78) | ADRA1AMCHR1DRD2ADRA1DADRA1B | |
| SCHEMBL6718967 | 0.87 | ADRA1A (0.77) | ADRA1AMCHR1DRD2ADRA1DADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4151210-A2 | PYRIDINE-CARBOLINE DERIVATIVES AS MCHR1 ANTAGONISTS FOR USE IN THERAPY | Harmony Biosciences, LLC (US) | 2023-03-22 | — | — | EP | claimed |
| US-20230084144-A1 | THERAPEUTIC COMBINATIONS OF DRUGS AND METHODS OF USING THEM | CONSYNANCE THERAPEUTICS INC (US) | 2023-03-16 | — | — | US | claimed |
| CN-115590966-A | Therapeutic combinations of drugs and methods of use thereof | 康圣博施医药有限公司（US） | 2023-01-13 | — | — | CN | claimed |
| US-20230002377-A1 | THERAPEUTIC COMBINATIONS OF DRUGS AND METHODS OF USING THEM | HARMONY BIOSCIENCES MANAGEMENT, INC. | 2023-01-05 | — | — | US | claimed |
| CN-115350184-A | Therapeutic combinations of drugs and methods of use thereof | 康圣博施医药有限公司 | 2022-11-18 | — | — | CN | claimed |
| EP-4076527-A1 | THERAPEUTIC COMBINATIONS OF DRUGS AND METHODS OF USING THEM | Consynance Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | claimed |
| US-12324812-B2 | Glucopyranosyl derivatives and their uses | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2025-06-10 | — | — | US | disclosed |
| WO-2025094152-A1 | 18F AND11C RADIOLABELED MCHR1 PET LIGANDS | RICHTER GEDEON NYRT. (HU) | 2025-05-08 | — | — | WO | disclosed |
| EP-4525833-A2 | VETERINARY PHARMACEUTICAL FORMULATIONS | Increvet, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| EP-3045466-B2 | (2S,3R,4S,5S,6R)-2-[4-CHLORO-3-(4-ETHOXY-BENZYL)-PHENYL]-6-HYDROXYMETHYL-2-METHOXY-TETRAHYDRO-PYRAN-3,4,5-TRIOL PROPYLENE GLYCOL SOLVATE AS SGT2 INHIBITOR FOR THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2024-10-16 | — | — | EP | disclosed |
| CN-112209908-B | Glucopyranosyl derivatives and uses thereof | 东莞市东阳光新药研发有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| US-20230372374-A1 | VETERINARY PHARMACEUTICAL FORMULATIONS | INCREVET, INC. | 2023-11-23 | — | — | US | disclosed |
| EP-3997079-A1 | GLUCOPYRANOSYL DERIVATIVES AND THEIR USES | Sunshine Lake Pharma Co., Ltd. (CN) | 2022-05-18 | — | — | EP | disclosed |
| US-20220105057-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-04-07 | — | — | US | disclosed |
| US-20220079897-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-03-17 | — | — | US | disclosed |
| CN-111630058-B | Glucopyranosyl derivative and use thereof | 广东东阳光药业有限公司 | 2022-02-15 | — | — | CN | disclosed |
| US-20070043080-A1 | Substituted anilinic piperidines as MCH selective antagonists | MARZABADI MOHAMMAD R | 2007-02-22 | — | — | US | disclosed |
| US-20050154022-A1 | 4-aryl piperidines | H. LUNDBECK A/S | 2005-07-14 | — | — | US | disclosed |
| US-6727264-B1 | MELANIN CONCENTRATING HORMONE-1 RECEPTOR ANTAGONISTS; SLEEP, EATING, SEXUAL DISORDERS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230084144-A1 | THERAPEUTIC COMBINATIONS OF DRUGS AND METHODS OF USING THEM | MCHR1, MCHR2, MC1R | ADRA1A 94/4885MCHR1 1/4885DRD2 178/4885 |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | ADRA1A 4557/4885MCHR1 3572/4885DRD2 4158/4885 |
| US-20070043080-A1 | Substituted anilinic piperidines as MCH selective antagonists | MCHR1, MCHR2, MC1R | ADRA1A 46/4885MCHR1 1/4885DRD2 119/4885 |
| US-20220079897-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | ADRA1A 3089/4885MCHR1 3278/4885DRD2 985/4885 |
| US-20050154022-A1 | 4-aryl piperidines | MCHR1, MCHR2, MC1R | ADRA1A 39/4885MCHR1 1/4885DRD2 81/4885 |
| US-20230372374-A1 | VETERINARY PHARMACEUTICAL FORMULATIONS | SLC5A2, SLC5A1, SLC2A8 | ADRA1A 505/4885MCHR1 1247/4885DRD2 3160/4885 |
| US-20220105057-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | ADRA1A 3619/4885MCHR1 3389/4885DRD2 1744/4885 |
| US-12324812-B2 | Glucopyranosyl derivatives and their uses | SLC5A1, SLC5A2, UGGT1 | ADRA1A 804/4885MCHR1 3673/4885DRD2 1877/4885 |
| US-20230002377-A1 | THERAPEUTIC COMBINATIONS OF DRUGS AND METHODS OF USING THEM | MCHR1, MCHR2, MC1R | ADRA1A 123/4885MCHR1 1/4885DRD2 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.